An interventional study of biological collection in Digestive Cancer, Gynecologic Cancer and Breast Cancer, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.
Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Not applicable, Interventional, and Other
Among 63 studies in Gastrointestinal Neoplasms with a site in France — 27 open to participants now, 32 under way, 3 of them phase 3. Gastrointestinal Neoplasms · France.
Among the 63 studies in Gastrointestinal Neoplasms with a site in France, this one is the 2nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2017, is one of 23 with no phase, reaches primary completion later than 15 of the 31 other live ones, and was the 15th registered.
695 studies on the registry are indexed under Gastrointestinal Neoplasms; 209 are open to participants now.
Browse Gastrointestinal Neoplasms studies →27 of the 63 studies in Gastrointestinal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Genmab · Sites in France, United States, Australia and 8 more countries
University Hospital, Strasbourg, France · Sites in France
Pfizer · Sites in France, United States, Argentina and 14 more countries
GlaxoSmithKline · Sites in France, United States, Australia and 16 more countries
Verastem, Inc. · Sites in France, United States, Australia and 1 more country
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 122 (76%) set no upper age limit and 18 (11%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 15 · Phase 3 9
First in 2004; this study’s year is marked. 4 started in 2017.
This study's planned enrollment of 4,000 is above the median of 74 across 494 interventional studies indexed under Gastrointestinal Neoplasms.
Median enrollment 200 across the 51 interventional studies, 131 across the 10 observational. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 63 have an industry lead sponsor. The 10 most frequent:
Institut du Cancer de Montpellier - Val d'Aurelle is the lead sponsor of 142 studies on the registry; 47 are open to participants now.
Institut du Cancer de Montpellier - Val d'Aurelle has 3 studies filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
11 of the studies in Gastrointestinal Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07575854Centre Georges Francois LeclercA Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer | 2026-12-01 |
| NCT07782203University Hospital, Strasbourg, FranceEstablishment of a Biological Collection to Develop Translational Preclinical Models for the Study of Tumors and Diseases of the Gastrointestinal Tract | 2026-12-30 |
| NCT04268121GERCOR - Multidisciplinary Oncology Cooperative GroupEfficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas | 2027-01 |
| NCT05994521McGill University Health Centre/Research Institute of the McGill University Health CentreProphylactic EUS-guided Gastroenterostomy in Advanced Periampullary Cancers | 2027-02 |
| NCT06881303Assistance Publique Hopitaux De MarseilleImpact of Prior Identification and Education of Patients Requiring a Digestive Stoma for Fecal Diversion | 2027-03-01 |
Among the 63 studies in Gastrointestinal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The BCB is a tool:
The creation of a broad clinical and biological prospective base dedicated to different types of cancer is essential for the development of such projects.
Implementation of a translational research project is part of the Cancer Plan 2014-2019 and its axis 5 "Advancing clinical and translational research in oncology", and more precisely Action 5.1.
The national health strategy launched by the Minister of Health and the Minister of Research will allow a better integration between research, innovation, medicine and care for the benefit of patients and society.
Moreover, knowledge of mechanisms involved in the phenomena of tumor invasion, metastatic dissemination, resistance to treatment and companion testing is crucial for the emergence of new biomarkers and therapeutic innovation.
However, the study of the earliest phases of tumorigenesis as well as of the advanced stages of the disease are currently limited by the low availability of blood and tissue samples combined with quality and reliable clinical data.
To meet these demands, the research must then integrate databases creation open to researchers and the ongoing evaluation of the impact of projects on the health of cancer patients.
Integrated research associated with quality biological research is the guarantee of medical progress.
The multidisciplinary structure around collections of biological resources will enable the various actors to harmonize not only the collection but also the sharing of their data with a view to making them available for medico-scientific projects at a regional and national dimension. The Clinical Biological Database (BCB) should be used to identify and characterize new molecular markers for better diagnosis and / or treatment. It should also permit to optimize the collection of all this information, their integration and their transversal exploitation by different research disciplines (epidemiological, fundamental, translational, clinical).
The BCB is a tool:
The creation of a broad clinical and biological prospective base dedicated to different types of cancer is essential for the development of such projects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient in ICM at diagnosis
Exclusion Criteria:
samples of different natures: * Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. * Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out. In parallel to this biological collection, standardized clinical data will be entered into a database
Biological: biological collection
* Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. * Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.
Proportion of patients who consent to participate in the study
the proportion of patients who consent to participate in the study among the screened patients
Time frame: through study completion, an average of 1 year
Quality of life assessment at baseline for all participants in the study
Questionnaire assessment to measure the quality of life at baseline
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2017 (actual). Primary completion is estimated for Nov 2027, 124 months after the start.
Of 153 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 124 months is above that.
Counting every sponsor, half of 163 studies reached it within 35 months; a quarter within 17 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut du Cancer de Montpellier - Val d'Aurelle →